Clinical Trial

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
Protocol Amendment History 1 change
critical Recruitment opened 2026-03-31
Trial Details
NCT Number NCT07358546
Lead Sponsor GlaxoSmithKline
Conditions Non-alcoholic Fatty Liver Disease
Enrollment 32 participants
Start Date 2026-03-13
Primary Completion 2027-10-13 (estimated)
Study Completion 2027-10-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-09